Long‐Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open‐Label Extension Study

3yr extension study of this anti-interferon alfa agent (n=218) found the rate and pattern of adverse effects were consistent with those reported at 1yr and few discontinued owing to adverse effects. Clinical improvements at 1yr were reported to be sustained at 3yrs.

Arthritis & Rheumatology